

1 **A haemagglutination test for rapid detection of antibodies to SARS-CoV-2**

2

3 Alain Townsend^{1,2*}, Pramila Rijal^{1,2}, Julie Xiao¹, Tiong Kit Tan¹, Kuan-Ying A Huang³, Lisa
4 Schimanski^{1,2}, Jiangdong Huo⁴, Nimesh Gupta⁵, Rolle Rahikainen⁶, Philippa C Matthews^{7,8},
5 Derrick Crook^{7,9,10}, Sarah Hoosdally^{8,10}, Teresa Street⁹, Justine Rudkin¹¹, Nicole Stoesser^{7,9},
6 Fredrik Karpe¹², Matthew Neville¹², Rutger Ploeg¹³, Marta Oliveira¹³, David J Roberts^{14,15},
7 Abigail A Lamikanra¹⁴, Hoi Pat Tsang¹⁴, Abbie Bown¹⁶, Richard Vipond¹⁶, Alexander J
8 Mentzer¹⁷, Julian C Knight¹⁷, Andrew Kwok¹⁷, Gavin Screaton^{17,18}, Juthathip
9 Mongkolsapaya^{2,18,19}, Wanwisa Dejnirattisai¹⁷, Piyada Supasa¹⁷, Paul Klenerman⁸, Christina
10 Dold^{20,21}, Kenneth Baillie²², Shona C Moore²³, Peter JM Openshaw²⁴, Malcolm G Semple²³,
11 Lance CW Turtle²⁵, Mark Ainsworth²⁶, Alice Allcock¹⁷, Sally Beer²⁶, Sagida Bibi²⁰, Elizabeth
12 Clutterbuck²⁰, Alexis Espinosa²⁶, Maria Mendoza²⁶, Dominique Georgiou²⁶, Teresa Lockett²⁶,
13 Jose Martinez²⁶, Elena Perez²⁶, Veronica Sanchez²⁶, Giuseppe Scozzafava²⁶, Alberto
14 Sobrinodiaz²⁶, Hannah Thraves²⁶, Etienne Joly^{27*}

15

16 ¹MRC Human Immunology Unit, MRC Weatherall Institute, John Radcliffe Hospital, Oxford
17 OX3 9DS, UK

18 ²Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford,
19 Oxford, UK

20 ³Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University
21 and Division of Pediatric Infectious Diseases, Department of Pediatrics, Chang Gung Memorial
22 Hospital, Taoyuan, Taiwan

23 ⁴Structural Biology, The Rosalind Franklin Institute, Harwell Science & Innovation Campus,
24 OX11 0FA, UK

25 ⁵Vaccine Immunology Laboratory, National Institute of Immunology, Aruna Asaf Ali Marg,
26 New Delhi – 110067, India

27 ⁶Department of Biochemistry, University of Oxford, South Park Road OX1 3QU, UK

28 ⁷Department of Microbiology and Infectious Diseases, John Radcliffe Hospital, Headley Way,
29 Oxford OX3 9DU, UK

30 ⁸Nuffield Department of Medicine, University of Oxford, Medawar Building for Pathogen
31 Research, South Parks Road, Oxford OX1 3SY, UK

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

32 ⁹Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Headley
33 Way, Oxford OX3 9DU, UK

34 ¹⁰Oxford NIHR Biomedical Research Centre, John Radcliffe Hospital, Headley Way, Oxford OX3
35 9DU, UK

36 ¹¹Nuffield Department of Population Health, Big Data Institute, University of Oxford, Oxford,
37 OX3 7LF

38 ¹²Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
39 Medicine, University of Oxford, Oxford, UK

40 ¹³Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital,
41 Headington, Oxford OX3 9DU, UK

42 ¹⁴NHS Blood and Transplant, John Radcliffe Hospital, Headington, Oxford OX3 9BQ, UK

43 ¹⁵BRC Haematology Theme and Radcliffe Department of Medicine, University of Oxford, John
44 Radcliffe Hospital, Oxford, OX3 9DU

45 ¹⁶Porton Down, Public Health England, Manor Farm Road, Porton Down, Salisbury, SP4 0JG,
46 UK

47 ¹⁷Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK

48 ¹⁸Division of Medical Sciences, John Radcliffe Hospital, University of Oxford, Oxford, UK

49 ¹⁹Dengue Hemorrhagic Fever Research Unit, Office for Research and Development, Faculty of
50 Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

51 ²⁰Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 7LE, UK

52 ²¹NIHR Oxford Biomedical Research Centre, Centre for Clinical Vaccinology and Tropical
53 Medicine, University of Oxford, Oxford, UK

54 ²²Anaesthesia, Critical Care and Pain Medicine Division of Health Sciences, University of
55 Edinburgh, Edinburgh, UK

56 ²³NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of
57 Infection, Veterinary and Ecological Sciences, University of Liverpool

58 ²⁴National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London,
59 UK

60 ²⁵Tropical and Infectious Diseases Unit, Liverpool University Hospitals NHS Foundation Trust,
61 Liverpool, UK

62 ²⁶Oxford University Hospitals NHS Foundation Trust, Oxford, UK

63 ²⁷Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS,
64 Toulouse; France

65

66 *Corresponding Authors

67 Correspondence to Alain Townsend (alain.townsend@imm.ox.ac.uk) and Etienne Joly
68 (atnjoly@mac.com)

69

70 **ABSTRACT**

71 Serological detection of antibodies to SARS-CoV-2 is essential for establishing rates of
72 seroconversion in populations, detection of seroconversion after vaccination, and for seeking
73 evidence for a level of antibody that may be protective against COVID-19 disease. Several
74 high-performance commercial tests have been described, but these require centralised
75 laboratory facilities that are comparatively expensive, and therefore not available universally.
76 Red cell agglutination tests have a long history in blood typing, and general serology through
77 linkage of reporter molecules to the red cell surface. They do not require special equipment,
78 are read by eye, have short development times, low cost and can be applied as a Point of Care
79 Test (POCT). We describe a red cell agglutination test for the detection of antibodies to the
80 SARS-CoV-2 receptor binding domain (RBD). We show that the Haemagglutination Test
81 (“HAT”) has a sensitivity of 90% and specificity of 99% for detection of antibodies after a PCR
82 diagnosed infection. The HAT can be titrated, detects rising titres in the first five days of
83 hospital admission, correlates well with a commercial test that detects antibodies to the RBD,
84 and can be applied as a point of care test. The developing reagent is composed of a previously
85 described nanobody to a conserved glycoporphin A epitope on red cells, linked to the RBD from
86 SARS-CoV-2. It can be lyophilised for ease of shipping. We have scaled up production of this
87 reagent to one gram, which is sufficient for ten million tests, at a cost of ~0.27 UK pence per
88 test well. Aliquots of this reagent are ready to be supplied to qualified groups anywhere in
89 the world that need to detect antibodies to SARS-CoV-2, but do not have the facilities for high
90 throughput commercial tests.

91

92 **INTRODUCTION**

93 Red cell agglutination tests have a distinguished history. Since Landsteiner’s classic
94 observations in 1901 (Landsteiner, 1961) (English translation), they have been used for the

95 determination of blood groups (Schwarz & Dorner, 2003) detection of influenza viruses (Hirst,
96 1941) and in a wide variety of applications championed by Prof. Robin Coombs for the
97 detection of specific antibodies or antigens (Coombs, Mourant, & Race, 1945) (reviewed by
98 (Pamphilon & Scott, 2007)). They have the great advantage of being simple, inexpensive, can
99 be read by eye, and do not require sophisticated technology for their application. In the
100 recent era the linkage of an antigen to the red cell surface has become easier with the
101 possibility of fusing a protein antigen sequence with that of a single domain antibody or
102 nanobody specific for a molecule on the red cell surface (discussed in (Habib et al., 2013)).


103

104 We have applied this concept to provide a simple Haemagglutination Test (“HAT”) for the
105 detection of antibodies to the Receptor Binding Domain (RBD) of the SARS-CoV-2 spike
106 protein. The RBD is a motile subdomain at the tip of the SARS-CoV-2 spike protein that is
107 responsible for binding the virus to its ACE2 receptor. The RBD of betacoronaviruses folds
108 independently of the rest of the spike protein (Lan et al., 2020; Li, Li, Farzan, & Harrison, 2005;
109 Wang et al., 2020; Yan et al., 2020). This useful property provides an Achilles’ heel for the
110 virus and allows many potential applications in vaccine design (Dai et al., 2020; Mulligan et
111 al., 2020; Tan et al., 2020; Walls et al., 2020; Yang et al., 2020; Zha et al., 2020), and serology
112 (Amanat et al., 2020; Piccoli et al., 2020; The National SARS-CoV-2 Serology Assay Evaluation
113 Group, 2020), see also [www.gov.uk/government/publications/COVID-19-laboratory-](http://www.gov.uk/government/publications/COVID-19-laboratory-evaluations-of-serological-assays)
114 [evaluations-of-serological-assays](http://www.gov.uk/government/publications/COVID-19-laboratory-evaluations-of-serological-assays)). The majority of neutralising antibodies bind to the RBD
115 (Barnes et al., 2020; Piccoli et al., 2020), and the level of antibody to the RBD detected in
116 ELISA correlates with that of neutralising antibodies (Amanat et al., 2020; Piccoli et al., 2020;
117 Robbiani et al., 2020). We reasoned therefore that a widely applicable and inexpensive test
118 for antibodies to the RBD would be useful for research in settings where high throughput
119 assays were not available.

120

121 In order to link the SARS-CoV-2 RBD to red cells we selected the single domain antibody
122 (nanobody) IH4 (Habib et al., 2013), specific for a conserved epitope on glycophorin A.
123 Glycophorin A is expressed at up to 10^6 copies per red cell. The IH4 nanobody has previously
124 been linked to HIV p24 to provide a monomeric reagent that bound p24 to the red cell surface.
125 Antibodies to p24 present in serum cross-linked the p24 and agglutinated the red cells (Habib
126 et al., 2013). We have adapted this approach to detection of antibodies to SARS-CoV-2 by

127 linking the RBD of the SARS-CoV-2 spike protein to IH4 via a short (GSG)₂ linker to produce
 128 the fusion protein IH4-RBD-6H (Figure 1). Since we embarked on this project, another group
 129 has described preliminary results with an approach similar to ours, but using a fusion of the
 130 RBD to an ScFV against the H antigen to coat red blood cells with the SARS-2 RBD (Kruse et
 131 al., 2020).
 132
 133



134

135

136 **Figure 1. Haemagglutination Test (HAT) for detection of antibodies to SARS-CoV-2 Receptor**
 137 **Binding Domain.**

138 A) Concept of the HAT

139 B) Sequence of VHH(IH4)-RBD fusion protein. Residues underlined are encoded by cloning
 140 sites Agel (TG) and Sall (AST). The codon optimised cDNA sequence is shown in supplementary
 141 Information

142 C) SDS-PAGE gel of purified VHH(IH4)-RBD proteins. Three micrograms of protein were run on
 143 4-12% Bolt Bis-Tris under reducing conditions. 1: IH4-RBD produced in house in Expi293F cells,
 144 2: IH4-RBD produced by Absolute Antibody, Oxford in HEK293 cells.

145

146 **RESULTS**

147

148 **Production of the IH4-RBD Reagent**

149 The IH4-RBD sequence (Figure 1B) was codon optimised and expressed in Expi293F cells in a
150 standard expression vector (available on request). One advantage of this mode of production
151 compared to bacterially produced protein as used by Habib et al, is that the reagent will carry
152 the glycosylation moieties found in humans, which may play a role in the antigenicity of the
153 RBD (Pinto et al., 2020). The protein (with a 6xHis tag at the C-terminus for purification) was
154 purified by Ni-NTA chromatography which yielded ~160 mg/L. We later had one gram of the
155 protein synthesised commercially by Absolute Antibody, Oxford. The IH4-RBD protein ran as
156 single band at ~40 kDa on SDS PAGE (Figure 1C).

157

158 **Establishment of the Haemagglutination Test (HAT) with monoclonal antibodies to the RBD**

159 One purpose envisaged for the HAT is for use as an inexpensive Point of Care Test for
160 detection of antibodies in capillary blood samples obtained by a “finger-prick”. We therefore
161 wished to employ human red cells as indicators without the need for cell separation or
162 washes, to mimic this setting. The use of V-bottom microtiter plates to perform simplified
163 hemagglutination tests was first described over 50 years ago (Wegmann & Smithies, 1966).
164 In preliminary tests, we observed that 50 μ L of whole blood (K2EDTA sample) diluted 1:40 in
165 phosphate-buffered saline (PBS), placed in V-bottomed wells of a standard 96-well plate,
166 settled in one hour to form a button of red cells at the bottom of the well. The normal
167 haematocrit of blood is ~40% vol/vol, so this dilution provides ~1% red cells. If the plate was
168 then tilted, the red cell button flowed to form a “teardrop” in ~30 seconds (for example Figure
169 2A Row 8).


170

171 If serum or plasma samples are to be tested, a standard collection of 10 mL of Type O Rh-
172 negative (O-ve) blood into a K2EDTA tube will thus provide sufficient red cells for 8,000 test
173 wells.

174

175 A well characterised monoclonal antibody to the RBD, CR3022 (ter Meulen et al., 2006) added
176 to the red cells at between 0.5-32 ng/well in 50 μ L, did not agglutinate the cells on its own

177 (Figure 2A Row 8). The addition of the IH4-RBD reagent at between 12.5-800 ng/well (in 50
178 μ L PBS) induced a concentration dependent agglutination of the red cells, detected by the
179 formation of a visible mat or plug of agglutinated cells, and the loss of teardrop formation on
180 tilting the plate (Figure 2A). From repeated trials of this experiment we established that a
181 standard addition of 100 ng/well of the IH4-RBD developer (50 μ L of a stock solution of 2
182 μ g/mL in PBS) induced agglutination of 50 μ L of 1:40 human red cells in the presence of as
183 little as 2 ng/well of the CR3022 monoclonal antibody. The standardised protocol used for the
184 subsequent tests were thus performed in 100 or 150 μ L final volume, containing 100 ng of
185 the IH4-RBD developer, and 50 μ L 1:40 whole blood (\sim 1% v/v red cells \sim 0.5 μ L packed red
186 cells per reaction). After 60 minutes incubation at room temperature, we routinely
187 photographed the plates after the 30 s tilt for examination and reading.
188
189 The requirement for 100 ng of the IH4-RBD developer per test well means that the gram of
190 IH4-RBD protein we have had synthesised is sufficient for 10 million test wells at a cost of
191 approximately 0.27 UK pence per test.



192
193 **Figure 2. Haemagglutination with human monoclonal antibodies or nanobodies to the**
194 **SARS-CoV-2 RBD**

195 A) Titration of IH4-RBD and monoclonal Antibody CR3022 to RBD. Doubling dilutions of
196 CR3022 and IH4-RBD were prepared in separate plates. 50 μ L red cells (O-ve whole blood
197 diluted 1:40 in PBS) were added to the CR3022 plate, followed by transfer of 50 μ L titrated
198 IH4-RBD. From this titration, 100 ng/well of IH4-RBD was chosen for detection.

199 B) Detection of other anti-RBD monoclonal antibodies and ACE2-Fc. Monoclonal antibodies
200 were prepared in doubling dilutions in 50 μ L PBS from left to right, 50 μ L of 1:40 O-ve red cells
201 were added, followed by 50 μ L of IH4-RBD (2 μ g/mL in PBS). The end point was defined as the

202 last dilution without tear drop formation on tilting the plate for ~ 30 s. The binding sites for
203 CR3022, EY6A and ACE2 on RBD have been defined (Huo, Zhao, et al., 2020; Lan et al., 2020;
204 Yan et al., 2020; Zhou et al., 2020). EW-9B and EW-9C are monoclonal antibodies against non-
205 RBD epitopes on the spike protein (Huang et al., 2020). ACE2-Fc has been described (Huang
206 et al., 2020).

207

208 Having established a standard addition of 100 ng/well of the IH4-RBD reagent, we screened a
209 set of twelve human monoclonal antibodies, two divalent nanobodies, and divalent ACE2-Fc,
210 that are known to bind to the RBD (Huang et al., 2020; Huo, Le Bas, et al., 2020; Pinto et al.,
211 2020; Wrapp et al., 2020; Zhou et al., 2020). These reagents bind to at least three independent
212 sites on the RBD, and some are strongly neutralising and capable of profound ACE2 blockade
213 (Huang et al., 2020; Huo, Le Bas, et al., 2020). Twelve of the 15 divalent molecules
214 agglutinated red cells and titrated in the HAT to an end point between 2-125 ng/well, after
215 addition of 100 ng IH4-RBD (Figure 2B and Supplementary Table 1). Two monoclonal
216 antibodies, FD-5D and EZ-7A (Huang et al., 2020) and one divalent nanobody VHH72-Fc
217 (Wrapp et al., 2020), failed to agglutinate red cells in the presence of the IH4-RBD reagent.
218 However, if a monoclonal antibody to human IgG was added to the reaction (50 µL of mouse
219 anti-human IgG, Sigma Clone GG5 1:100), these molecules specifically agglutinated the red
220 cells (Supplementary Figure 1A, B). This result, analogous to the “indirect” Coombs Test
221 (Coombs et al., 1945; Pamphilon & Scott, 2007), suggested that these three molecules had
222 bound to the RBD associated with the red cells but failed to crosslink to RBDs on neighbouring
223 red cells. However, these could be crosslinked by the anti IgG reagent. Monoclonal antibodies
224 to other regions of the spike protein (EW-9B, EW-9C and FJ-1C) failed to agglutinate red cells
225 (Figure 2B, Supplementary Table 1). Finally we looked at the effect of a divalent ACE2-Fc
226 molecule constructed by fusing the peptidase domain of ACE2 (amino acids 19-615) to the
227 hinge and Fc region of human IgG1 (described in (Huo, Le Bas, et al., 2020). ACE2-Fc
228 agglutinated red cells strongly in the presence of 100 ng/well of the IH4-RBD developer,
229 titrating to ~ 4 ng/well (Figure 2B rows 7,8).

230

231 In summary, these results showed that all of the known epitopes bound by characterised
232 monoclonal antibodies were displayed by the IH4-RBD reagent, as well as the ACE2 binding
233 site, and could mediate agglutination by specific antibodies, divalent nanobodies, or ACE2-Fc.


234

235 **Agglutination by plasma from donors convalescing from COVID-19**

236 These experiments established the conditions for detection of haemagglutination by
237 monoclonal antibodies to the RBD, in particular the optimum concentration of IH4-RBD of
238 100 ng/well. We then proceeded to look for haemagglutination by characterised plasma from
239 COVID-19 convalescent donors. In the first trial we tested eighteen plasma samples from
240 patients with mostly mild illness, that had been characterised with a quantitative ELISA to
241 detect antibodies to the RBD (Peng et al., 2020). For these experiments we used fresh O-ve
242 blood (K2EDTA sample) diluted to 1:40 as a source of red cells to avoid agglutination by
243 natural agglutinins in the plasma. Plasmas were titrated by doubling dilution from 1:20 in 50
244 μ L, then 50 μ L of 1:40 O-ve red cells were added, followed by addition of 100 ng of the IH4-
245 RBD in 50 μ L PBS. After one-hour incubation, plates were tilted for ~30 seconds,
246 photographed and read. The titre of agglutination was assessed by complete loss of teardrop
247 formation by the red cells, any formation of a teardrop was regarded as negative. Figure 3A
248 shows that the HAT titre matched the RBD ELISA results. Four samples were scored as
249 negative in both assays. The remaining results showed that in general the HAT titre increased
250 with the ELISA end point titre. One sample gave a positive titre of 1:320 in the HAT but was
251 negative in ELISA (indicated with an arrow). We investigated this sample with a developer
252 composed of the IH4 nanobody without the RBD component, which revealed that
253 agglutination was RBD dependent (not shown). This sample was also positive at 1:1123 in an
254 ELISA for full length spike protein (not shown), which suggests that the antibodies contained
255 in this serum recognised epitope(s) present on the RBD exposed in the HAT, but not on the
256 RBD in the RBD-ELISA reference test (Peng et al., 2020). The highest titre detected in these
257 samples by the HAT was 1:1280 (Figure 3B).

258

259 These preliminary results showed that the HAT could detect antibodies to the RBD in plasma
260 samples from convalescent patients in a similar manner to an ELISA test, but were not
261 sufficient to establish the sensitivity and specificity of the HAT.



262

263 **Figure 3. Titration of stored plasma in the agglutination assay.**

264 A) Eighteen plasma samples from mild cases were compared for titration in the HAT with 1:40
265 O-ve whole blood from a seronegative donor, and endpoint titre in an RBD ELISA (Peng et al.,
266 2020)). Four samples were negative in both assays. The data point marked with an arrow on
267 the graph (plasma 2 on the plate, Fig 3B) was checked with a reagent composed of IH4 without
268 RBD and shown to be dependent on antibodies to the RBD. This sample did score positive for
269 antibodies to full length spike in an ELISA (EPT 1:1123).

270 B) An example of titration: positive agglutination endpoints (loss of teardrop) are marked with
271 a black solid-line circle, partial teardrops are marked with a dotted-line circle.

272

273 Sensitivity and specificity of the Haemagglutination Test

274 To formally assess the sensitivity and specificity of the HAT we collected a set of 98 “positive”
275 plasma samples from donors diagnosed with COVID-19 by RT-PCR at least 28 days prior to
276 sample collection (NHS Blood and Transplant), and 199 “negative” serum samples from
277 healthy donors from the pre-COVID-19 era (Oxford Biobank). The samples were randomised
278 before plating. The test wells were arranged in duplicate to contain serum/plasma at 1:40
279 dilution, and 1:40 O-ve red cells in 50 μ L. 100 ng of IH4-RBD in 50 μ L PBS was added to one
280 well of the pair, 50 μ L of PBS to the other (as a negative control). The negative control is
281 important because in rare cases, particularly in donors who may have received blood
282 transfusions, the sample may contain antibodies to non-ABO or Rhesus D antigens. After
283 development, the plates were photographed, and read by two independent masked
284 observers. Complete loss of teardrop was scored as positive, any flow in the teardrop as

285 negative. These rules were established before setting up the tests. Disagreements (7%
286 overall) were resolved by accepting the weaker interpretation – i.e. if one observer scored
287 positive but the other negative, the well was scored as negative. Having completed the
288 scoring the columns of samples were re-randomised and the test and scoring repeated.

289

290 Examples of test wells and scoring are shown in Figure 4. The red cells in the negative control
291 (PBS) wells formed a clear teardrop. Red cells in positive wells (indicated with a solid ring)
292 settled either into a mat or a button that failed to form any teardrop on tilting for 30 seconds.
293 Occasional wells (15 of 297) formed a “partial” teardrop (shown by a dashed ring). These were
294 scored as negative by prior agreement.

295


296 With these rules in place we obtained in the first run sensitivity 88%, specificity 99%, and in
297 the second run sensitivity 93%, specificity 99% (Figure 4). The Siemens Atellica
298 Chemiluminescence assay for detection of IgG antibodies to the RBD was run in parallel on
299 293 of these 297 samples and gave sensitivity 100%, specificity 100% for this sample set.

300

301 We decided prior to this formal assessment to score wells with partial teardrop formation as
302 negative, as these wells tended to give rise to disagreements between scorers and were not
303 very helpful. Fifteen of 297 wells gave a partial teardrop. Six of these fifteen were from PCR-
304 ve donors and scored negative on the Siemens assay, 9/16 were from PCR+ve donors and
305 were Siemens positive. If partial teardrops were scored as positive, the sensitivity of the two
306 assays increased to 97% and 99% (from 88% and 93%), but specificity was reduced to 96%
307 and 98% (from 99%). This small loss of specificity would be unacceptable in sero-surveys
308 where the expected prevalence of previous SARS-CoV-2 infection was low.

309

A Examples from screen of 297 test samples



B Operating Characteristics of the Haemagglutination Test

98 PCR +ve Samples ≥ 28 days post diagnosis
199 –ve samples from The Oxford Biobank Pre Covid-19

| 11 June | | | |
|--|---------|---------|-----|
| Sensitivity and Specificity Calculator | | | |
| +VE = No Teardrop | | | |
| | HAT +VE | HAT -VE | |
| PCR +VE | 86 | 12 | 98 |
| PCR -VE | 1 | 198 | 199 |
| | 87 | 210 | 297 |
| Sensitivity % | 88 | | |
| Specificity % | 99 | | |
| Likelihood Ratio | 174.6 | | |
| 13 June REPEAT | | | |
| Sensitivity and Specificity Calculator | | | |
| +VE = No Teardrop | | | |
| | HAT +VE | HAT -VE | |
| PCR +VE | 91 | 7 | 98 |
| PCR -VE | 1 | 198 | 199 |
| | 92 | 205 | 297 |
| Sensitivity % | 93 | | |
| Specificity % | 99 | | |
| Likelihood Ratio | 184.8 | | |

310

311 **Figure 4. Operating characteristics of the HAT.**

312 A) The test set of 297 randomised plasma samples were diluted 1:40 mixed with 1:40 O-ve
313 blood in two columns. IH4-RBD (100 ng in 50 μ L) was added to the test samples, and PBS to
314 negative control wells. The plates were incubated at room temperature for one hour to allow
315 the red cell pellet to form, then tilted for ~ 30 seconds to allow a teardrop to form. Complete
316 loss of teardrop was scored as positive agglutination (marked with a black solid-line circle).
317 Full teardrop or partial teardrop (marked with a dotted-line circle) were scored negative. The
318 samples in columns were re-randomised and tested for a second time two days later.

319 B) Contingency table showing the operating characteristics of the HAT.

320

321 **HAT in the Hospital Setting**


322 We next assessed the HAT in the setting of patients recently admitted to hospital (the first
323 five days) through access to the COMBAT collection of samples (see methods). This set
324 comprised 153 plasma samples from donors diagnosed with COVID-19 by PCR, with clinical
325 syndromes classified as « Critical », « Severe », « Mild », and « PCR positive Health Care
326 Workers ». Seventy-nine control plasma samples donated in the pre-COVID-19 era were

327 obtained either from patients with bacterial sepsis (54 samples), or healthy volunteers (25
328 samples). Samples were titrated in 11 doubling dilutions of 50 μ L from 1:40 – 1:40,096
329 (columns 1-11). Column 12 contained 50 μ L PBS as a negative control. 50 μ L of 1:40 O-ve
330 whole blood was added, followed by 50 μ L of 2 μ g/mL IH4-RBD (100 ng/well). In parallel, all
331 of the 153 samples from PCR positive donors were assessed by the Siemens Atellica
332 Chemiluminescence test for antibodies to the RBD of the spike protein. The HAT scores (as
333 the number of doubling dilutions of the sample required to reach the endpoint of complete
334 loss of teardrop), and representative agglutination results are shown in figure 5A. In Figure
335 5B the HAT scores are plotted with their related Siemens test scores.

336


337 None of the seventy-nine negative control samples scored as positive in the HAT at a dilution
338 of 1:40, thus providing 100% specificity in this set of samples. The HAT detected 131/153 (86%
339 sensitivity) of the samples from PCR-diagnosed donors within the first five days of hospital
340 admission, whereas the Siemens test detected 113/153 (74%). On day 5 the HAT detected
341 41/45 (91% sensitivity). Two samples had an endpoint greater than 11 doubling dilutions in
342 the HAT, and required a repeat measurement spanning two plates. These two samples
343 titrated to 13 doubling dilutions (1: 163,840). Unmasking the samples revealed that both were
344 acquired from an elderly lady with mild disease on days 3 and 5 of her admission. The range
345 of positive titres detected by HAT was broad: 1 to 13 doubling dilutions (1:40 – 1:163,840). A
346 correlation coefficient with the Siemens test could not be calculated as the latter has a ceiling
347 score of 10 (Figure 5B). A comparison of the two tests in a contingency table with cut-off of
348 1:40 (first doubling dilution) for HAT, and a score \geq 1 for the Siemens test (as defined by the
349 manufacturer), showed a strong correlation between the two tests for detection of antibodies
350 to the RBD ($P < 0.0001$; two-tailed Fisher's exact test, Figure 5B). Fifty-four of the 153 samples
351 were from 25 donors with COVID-19 from whom repeated samples were taken on days 1, 3,
352 or 5 of admission. The HAT detected a rise in agglutination titre over the first five days of
353 admission in 17/25 (68%) of these patients (Table 1). Reductions in titre were not detected.

A Titration in HAT by doubling dilution



Donors were grouped according to clinical criteria; HCW = Front Line Health Care Workers; Sepsis = Samples with patients with Sepsis prior to Covid-19 pandemic; Healthy = Healthy volunteers prior to Covid-19; DD 1 = 1:40. Actual Titre = 20×2^{DD} .

B



354

355 **Figure 5. Titration of the set of 232 samples in the HAT**

356 A) The collection included 32 samples from 24 Critical patients, 62 samples from 48 Severe,
 357 39 samples from 32 Mild, 20 single samples from health care workers (HCW), 54 samples from
 358 43 patients with unrelated sepsis in the pre-COVID-19 era, 25 samples from healthy
 359 unexposed controls. Median is indicated by a red line. DD: doubling dilutions.

360 B) Comparison to Siemens Result (anti RBD) with HAT titre by doubling dilution for 153
 361 samples from Critical, Severe, Mild and HCW SARS-CoV-2 PCR positive donors.

362

363 These results showed that in the setting of hospital admission in the UK for suspected COVID-
 364 19 disease, the HAT has an overall sensitivity of 86% and specificity of 100% by day five, and
 365 frequently (68%) detected a rise in HAT titre during the first five days of admission. In this
 366 context the HAT performed at least as well as the commercially available Siemens Atellica
 367 Chemiluminescence assay (74%) for the detection of antibodies to the RBD of SARS-CoV-2
 368 spike protein. Twenty samples were negative in both tests, but nine of these were taken on

369 day 1 of admission, which suggests that both tests have lower detection levels early in the
370 course of hospital admission, before the antibody response has fully developed.

371

372 The O-ve blood used as indicator for this experiment was collected into a heparin tube, and
373 then transferred to a K2EDTA tube. In order to be sure that the presence of heparin in the red
374 cells had not altered the behaviour of the test, and to confirm the robustness of the results,
375 we repeated the titrations on all of the 232 samples 34 days later, with fresh O-ve red cells
376 from a different donor collected as usual into a K2EDTA tube. The results are shown in
377 supplementary figures 2A-C. Specificity of the HAT remained at 100% (none of the 79 control
378 samples were detected as positive at 1:40). The correlation with the previous assay was
379 strong ($R^2 = 0.975$), and 99% of the 232 titrations were within one doubling dilution of the
380 matched earlier measurement. The slope of the correlation was 0.94 (95% CI 0.92-0.96),
381 significantly less than 1. This was due to a proportion of results titrating to one doubling
382 dilution lower titre. However, this had only a small impact on sensitivity (81% from 86%),
383 which was still an improvement on the Siemens test (74%) in this context of the first five days
384 of hospital admission.

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400 **Table 1. Fifty-four samples from 25 donors who were sampled repeatedly during the first**
 401 **five days in hospital.**


| No | Case | Day post-hospitalisation | | | | |
|----|------|--------------------------|---|--------|---|--------|
| | | 1 | 2 | 3 | 4 | 5 |
| 1 | C2 | | | 40 | | 160 |
| 2 | C6 | | | 40 | | 80 |
| 3 | C7 | 0 | | | | 0 |
| 4 | C8 | | | 320 | | 1280 |
| 5 | C9 | 40 | | | | 2560 |
| 6 | C10 | 320 | | 320 | | |
| 7 | C23 | 0 | | 160 | | 640 |
| 8 | S5 | 80 | | 160 | | |
| 9 | S6 | 1280 | | 1280 | | 2560 |
| 10 | S7 | 80 | | | | 2560 |
| 11 | S12 | 640 | | 1280 | | |
| 12 | S13 | 0 | | 40 | | 320 |
| 13 | S14 | | | 640 | | 640 |
| 14 | S17 | | | 2560 | | 2560 |
| 15 | S20 | 160 | | 320 | | |
| 16 | S31 | 40 | | | | 1280 |
| 17 | S41 | | | 640 | | 1280 |
| 18 | S43 | | | 40 | | 160 |
| 19 | S48 | | | 1280 | | 2560 |
| 20 | M9 | | | 0 | | 160 |
| 21 | M11 | 0 | | 0 | | 0 |
| 22 | M13 | | | 0 | | 0 |
| 23 | M14 | | | 163840 | | 163840 |
| 24 | M25 | 40 | | | | 640 |
| 25 | M30 | | | 320 | | 320 |

402
 403 C: Critical, S: Severe, M: Mild

404
 405 **HAT as a Point of Care Test on Capillary Samples**

406 The HAT is designed to detect antibodies to the RBD starting at a serum dilution of 1:40, and
 407 we have found that that 50 µL of 1:40 dilution of whole blood provides an optimal
 408 concentration of red blood cells for detection by agglutination in V-bottomed 96 well plates.
 409 We have not completed an extensive analysis of the HAT as a Point of Care Test. However,
 410 we have preliminary evidence that lyophilised IH4-RBD sent to the National Institute of
 411 Immunology, New Delhi, functions as a Point of Care Test on capillary blood obtained by
 412 finger-prick. In Figure 6, three positive (donors 1, 2 and 3) and three negative (donors 4, 5 and
 413 6) HAT results are compared to a standard ELISA for detection of antibodies to the RBD.

414



415

416 **Figure 6. HAT as a point of care test.**

417 Capillary blood samples were obtained by lancet. Antibodies to the RBD were detected by
 418 HAT on autologous red cells in the sample in “Test” wells (plasma at 1:40) after addition of
 419 100 ng/well IH4-RBD (see methods). NC, Negative Control (PBS replaces IH4-RBD); PC Postive
 420 Control (20 ng/well CR3022, an anti-RBD monoclonal antibody added). In parallel, after
 421 removal of red cells, the plasma was tested in a standard ELISA for detection of antibodies to
 422 the RBD. Low levels of antibody detected in the ELISA were sufficient to give a positive result
 423 in the HAT.

424

425 Further work is needed to establish the operating characteristics of the HAT as a Point of Care
 426 Test on capillary samples. We provide a suggested operating procedure for capillary samples
 427 in methods.

428

429 **Distribution of the IH4-RBD as lyophilised protein**

430 In order to ship the IH4-RBD reagent efficiently we have examined the effects of lyophilisation
 431 and reconstitution with water. IH4-RBD synthesised for the purpose of distribution was
 432 provided at 5 mg/mL in PBS by Absolute Antibody Ltd, Oxford. Two hundred microlitre
 433 aliquots (1 mg, enough for 10,000 test wells) were lyophilised overnight and stored at -20 °C.
 434 Aliquots were thawed, reconstituted with 200 µL double distilled water and titrated against
 435 the pre-lyophilisation material. No change in the titration occurred. We have synthesised one
 436 gram of IH4-RBD, sufficient for 10 million test wells. This is available free of charge for any
 437 qualified group anywhere in the world in aliquots of 1 mg (20,000 test wells).

438

439 **DISCUSSION**

440 The COVID-19 pandemic has had a particularly gruelling influence on the world economy, and
441 on most populations of the world. The appearance of such a new highly contagious virus will
442 probably not be a unique occurrence in the decades ahead. One of the lessons learned is the
443 importance of developing affordable serological tests for detection of immune responses to
444 SARS-CoV-2. Commercial antibody tests are not widely available to low- and middle-income
445 countries, and lateral flow assays, while offering early promise as a near-patient test, have
446 failed to deliver in terms of performance metrics, are expensive, and there are concerns about
447 significant batch-to-batch variation (Adams et al., 2020). By contrast, the advantages of the
448 HAT are the low cost of production of its single reagent (~0.27 UK pence per test well), better
449 performance than most lateral flow devices (Adams et al., 2020), and versatility in not
450 requiring anything other than a source of O-ve blood (10 mL of K2EDTA blood provides
451 enough for 8,000 tests), an adjustable pipette, PBS, and a standard 96 well V-bottomed plate.

452

453 We have demonstrated that the HAT functions as a viable test for the presence of antibodies
454 to the RBD of the SARS-CoV-2 spike protein in stored serum/plasma samples, using O-ve red
455 cells as indicators. In the formal assessment of sensitivity and specificity we recorded an
456 average 90% sensitivity and 99% specificity (Likelihood Ratio ~175), compared to 100%
457 sensitivity and 100% specificity for the Siemens Atellica Chemiluminescence test on the same
458 set of samples. The “positive” samples were selected to have been taken at least 28 days after
459 a positive PCR test. These conditions are optimal for serological tests by allowing time for a
460 rise in antibodies. The sensitivity of ~90% and specificity of 99% did not reach the level of
461 98% for both recommended by the UK MHRA (The National SARS-CoV-2 Serology Assay
462 Evaluation Group, 2020), or 99.5% for both recommended by the Infectious Disease Society
463 of America (Hanson et al., 2020). However, these values are still consistent with a useful test
464 in appropriate contexts, provided that users are fully aware of the operating characteristics
465 and interpret the results correctly.

466

467 The sensitivity of the single point HAT can be enhanced (to ~98%) if wells with partial teardrop
468 formation are scored as positive. However, this improvement in sensitivity is gained at the
469 expense of a reduced specificity (to ~97%). If partial teardrops are to be scored as positive in
470 the spot test at 1:40, we recommend obtaining confirmation for these by ELISA. Improvement

471 in the operating characteristics of the HAT may be possible by a systematic analysis of buffer
472 composition and experimental conditions, and is being investigated. We have deliberately
473 kept complexity to a minimum, and thus all dilutions were made in standard PBS, and for the
474 moment we recommend scoring wells with partial teardrop formation as negative.

475

476 It is interesting that the HAT titrations actually performed a little better than the Siemens test
477 on 153 stored plasma samples from donors during the first five days of their hospital
478 admission (note that symptom onset may have been several days earlier), in whom it
479 detected 86% (81% in the repeat) of samples from PCR-diagnosed donors, compared to 74%
480 for the Siemens test, and gave 100% specificity for the sample set containing control plasma
481 from patients with sepsis and healthy controls. We speculate that at this early period of the
482 COVID-19 illness the immune response may be dominated by IgM that would be expected to
483 be particularly efficient at crosslinking the IH4-RBD labelled red cells. In addition, of the
484 twenty-five donors who were tested more than once in the first five days in hospital, the HAT
485 detected a rise in titre in seventeen (68%). A fixed high titre was detected in a further five to
486 provide a sensitivity of 88% in these twenty-five cases. In situations of high clinical suspicion,
487 the HAT could potentially have a place as a helpful test to support the diagnosis of COVID-19
488 by detecting a rising titre of antibodies to the RBD during hospital admission. In patients with
489 a prior probability of a diagnosis of COVID-19 of ~10%, the likelihood ratio of ~175 for the HAT
490 provides a posterior probability of ~95% for this diagnosis. However, it is essential that if
491 clinicians use a rising titre in the HAT as a diagnostic aid, they should be aware of the relatively
492 low sensitivity (~68%) in this context.

493

494 With a specificity of 99%, the HAT could be employed for epidemiological surveys of the
495 seropositive rate in stored serum/plasma samples from populations with a moderate
496 expected prevalence ~10%, which would entail a negative predictive value of ~90%. The HAT
497 may be useful to detect seroconversion after vaccination, and for the identification of
498 potential donors of high titre plasma for therapy, if the clinical trials that are in progress
499 demonstrate a benefit. In the absence of knowledge about the level of antibody that indicates
500 protection, the HAT should not be used to provide personal results to individuals, as discussed
501 by the UK Royal College of Pathologists ([https://www.rcpath.org/profession/on-the-](https://www.rcpath.org/profession/on-the-agenda/COVID-19-testing-a-national-strategy.html)
502 [agenda/COVID-19-testing-a-national-strategy.html](https://www.rcpath.org/profession/on-the-agenda/COVID-19-testing-a-national-strategy.html)). Finally, we show that the lyophilised

503 IH4-RBD reagent sent to New Delhi functioned as expected in preliminary point of care testing
504 on capillary samples obtained by finger-prick. However, additional evidence is needed to
505 show that the sensitivity and specificity of the HAT, applied as a Point of Care Test in this way,
506 are comparable to the tests on stored plasma samples, as stressed by the IDSA guideline on
507 serological testing (Hanson et al., 2020). This will need to be done in field conditions, which is
508 planned.

509

510 The technique required for applying the HAT can be learned in a day by a trained laboratory
511 technician, paramedic, nurse or doctor. We have produced one gram of the developing IH4-
512 RBD reagent (enough for ten million test wells) and offer to ship lyophilised aliquots of this
513 material (sufficient for 10,000 tests) anywhere in the world, free of charge, for use as a
514 research reagent for serological studies of COVID-19.

515

516 **METHODS**

517

518 **Sample Collection and Ethics**

519 **Figures 1,2:** Control whole blood (K2EDTA) as a source of red cells was collected from a
520 healthy donor after informed consent.

521

522 **Figure 3:** Pre-pandemic negative controls: these samples were collected from healthy adults
523 in the Oxfordshire region of the UK between 2014 and 2016, ethics approval: Oxfordshire
524 Clinical Research Ethics Committee 08/H0606/107+5. Positive sample set: these were
525 convalescent plasma donors recruited by NHS Blood and Transplant (NHSBT), ethics approval
526 (NHSBT; RECOVERY [Cambridge East REC (ref: 20/EE/0101)] and REMAP-CAP [EudraCT 2015-
527 002340-14] studies).

528

529 **Figures 4, 5 and Table 1:** Known COVID-19 positive samples were collated from three ethically
530 approved studies: Gastro-intestinal illness in Oxford: COVID substudy [Sheffield REC,
531 reference: 16/YH/0247] ISARIC/WHO, Clinical Characterisation Protocol for Severe Emerging
532 Infections [Oxford REC C, reference 13/SC/0149], the Sepsis Immunomics project [Oxford REC
533 C, reference:19/SC/0296]) and by the Scotland A Research Ethics Committee (Ref:
534 20/SS/0028). Patients were recruited from the John Radcliffe Hospital in Oxford, UK, between

535 March and May 2020 by identification of patients hospitalised during the SARS-COV-2
536 pandemic and recruited into the Sepsis Immunomics and ISARIC Clinical Characterisation
537 Protocols. Time between onset of symptoms and sampling were known for all patients and if
538 labelled as convalescent patients were sampled at least 28 days from the start of their
539 symptoms. Written informed consent was obtained from all patients. All patients were
540 confirmed to have a test positive for SARS-CoV-2 using reverse transcriptase polymerase
541 chain reaction (RT-PCR) from an upper respiratory tract (nose/throat) swab tested in
542 accredited laboratories. The degree of severity was identified as mild, severe or critical
543 infection according to recommendations from the World Health Organisation. Severe
544 infection was defined as COVID-19 confirmed patients with one of the following conditions:
545 respiratory distress with RR>30/min; blood oxygen saturation<93%; arterial oxygen partial
546 pressure (PaO₂) / fraction of inspired O₂ (FiO₂) <300 mmHg; and critical infection was defined
547 as respiratory failure requiring mechanical ventilation or shock; or other organ failures
548 requiring admission to ICU. Comparator samples from healthcare workers with confirmed
549 SARS-CoV-2 infection who all had mild non-hospitalised disease were collected under the
550 Gastro-intestinal illness in Oxford: COVID sub-study, and samples from patients with
551 equivalently severe disease from non-COVID infection were available from the Sepsis
552 Immunomics study where patients presenting with significantly abnormal physiological
553 markers in the pre-pandemic timeframe had samples collected using the same methodology
554 as that applied during the COVID pandemic. Blood samples were collected in K2EDTA
555 vacutainers and PBMCs were separated from plasma using Sepmate isolation tubes
556 (STEMCELL Technologies) and plasma was used in the downstream HAT assay.

557

558 **Figure 6:** Capillary samples were collected from members of institute staff with informed
559 consent (New Delhi, India). The study is a part of the COVID-19 project 'IPA/2020/000077'.
560 The project has been approved by the Institutional Human Ethics Committee; Ref. no. -
561 IHEC#128/20.

562

563 **Cloning, Expression and Purification of VHH(IH4)-RBD**

564 The codon-optimised gene encoding IH4-RBD sequence (Figure 1B and supplementary for the
565 cDNA sequence) was synthesized by Integrated DNA Technologies. The gene was cloned in
566 to the AbVec plasmid (Genbank FJ475055) using the restriction sites AgeI and HindIII (the

567 vector supplied the signal sequence). **This expression plasmid for IH4-RBD is available on**
568 **request.** Protein was expressed in Expi293F™ cells using the manufacturer's protocol
569 (Thermo Fisher). Protein supernatant was harvested on day 5/6 after transfection, spun and
570 0.22 µm filtered. The protein was affinity-purified using a His-Trap HP column (Cytiva). Binding
571 buffer consisted of 20 mM Sodium Phosphate, 150 mM NaCl and 20 mM Imidazole at pH 7.4,
572 and the elution buffer of 500 mM Imidazole in 1 x binding buffer. Protein was concentrated
573 using 15 ml Vivaspin 30 kDa MWCO filter and then buffer exchanged to PBS using a 10 ml 7
574 kDa Zebaspin column (Thermo Fisher).

575

576 For large scale production, the protein was synthesized by Absolute Antibody Ltd, Oxford
577 using the same plasmid construct in HEK293 cells.

578

579 **Lyophilisation of IH4-RBD and CR3022 monoclonal antibody**

580 For lyophilisation, 200 µL (1 mg) of IH4-RBD (5 mg/mL) and 100 µL (200 µg) CR3022 mAb (2
581 mg/mL) in PBS buffer prepared in Protein Lo-Bind microcentrifuge tube (Fisher Scientific)
582 were frozen at -80 °C and further cooled down to -196 °C using liquid nitrogen. Pre-cooled
583 samples were transferred to Benchtop K freeze-dryer (VirTis) with chamber at 49 µbar and
584 condenser pre-cooled to -72.5 °C. The samples were freeze-dried for a minimum of 24 h,
585 wrapped in Parafilm (Merck) and stored at -20 °C. Lyophilised sample was reconstituted in
586 the same original volume of MilliQ water.

587

588 **Indirect ELISA to detect SARS-CoV-2 specific IgG (Figure 6)**

589 A standard indirect ELISA was used to determine the SARS-CoV-2 specific IgG levels in plasma
590 samples. A highly purified RBD protein from SARS-CoV-2 Wuhan strain (NR-52306, BEI
591 Resources, USA), expressed in mammalian cells, was used to capture IgG in the plasma
592 samples. Briefly, ELISA plates (Nunc, Maxisorp) were coated with 100 µL/well of RBD antigen
593 diluted in PBS (pH 7.4) at the final concentration of 1 µg/mL and incubated overnight at 4°C.
594 Plates were washed three times with washing buffer (0.05% Tween-20 in PBS) followed by
595 the incubation with blocking buffer (3% Skim milk and 0.05% Tween-20 in PBS). The 3-fold
596 serially diluted heat inactivated plasma samples in dilution buffer (1% Skim milk and 0.05%
597 Tween-20 in PBS) were added into the respective wells, followed by incubation at room
598 temperature for 1 hour. After incubation, plates were washed, and anti-human IgG

599 conjugated with Horseradish Peroxidase (HRP) (Southern Biotech) was added in each well.
600 After 1 h incubation, plates were washed and developed by OPD-substrate (Sigma-Aldrich) in
601 dark at room temperature. The reaction was stopped using 2N HCl and the optical density
602 (OD) was measured at 492 nm. The RBD-antigen coated wells that were added with sample
603 diluent alone were used as the blank. The OD values from sample wells were plotted after
604 subtracting the mean of OD values obtained in the blank wells.

605

606 **Equipment and Reagents for HAT**

- 607 • O-ve blood as a source of red cells collected in K2EDTA tube, diluted **in PBS to 1:20 or**
608 **1:40 as needed**. Resuspend by inverting gently ~12 times.
- 609 • BD Contact Activated Lancet Cat. No. 366594 (2 mm x 1.5 mm)
- 610 • 100 µL, 20 µL pipettes, Multichannel pipettes
- 611 • V-bottomed 96-well plates (Greiner Bio-One, Cat. No. 651101, Microplate 96-well, PS,
612 V-bottom, Clear, 10 pieces/bag)
- 613 • Eppendorf Tubes
- 614 • K2EDTA solution (add 5 mL PBS to 10 mL K2EDTA blood collection tube = 3.6 mg
615 K2EDTA/mL, store at 4 °C)
- 616 • Phosphate Buffered Saline Tablets (OXOID Cat. No. BR0014G)
- 617 • IH4-RBD Reagent diluted 2 µg/mL in PBS. This remains active for at least 1-2 weeks
618 stored at 4 °C
- 619 • V-bottomed 96-well plates, numbered, dated, timed (helps when timing many plates)
- 620 • Positive control monoclonal antibody CR3022 diluted to 2 µg/mL in PBS

621

622 **Other Reagents**

623 Monoclonal antibody to human IgG (Gamma chain specific) Clone GG-5 Sigma Cat. No. I5885

624

625 **1. Spot test on Stored Serum/Plasma samples (Figure 4).**

- 626 1. Plate out 50 µL of **1:20** serum/plasma in alternate columns 1,3,5,7,9,11 (add 2.5 µL
627 sample to 47.5 µL PBS).
- 628 2. Add 50 µL **1:20** O-ve blood collected in (**so that now sample is diluted to 1:40 and red**
629 **cells at ~1% v/v)**

- 630 3. Mix and transfer 50/100 μL to neighbouring columns 2,4,6,8,10,12 for -ve controls.
631 The negative control is important because in rare cases, particularly in donors who
632 have received blood transfusions, the sample in principle may contain antibodies to
633 non-ABO or Rhesus D antigens.
- 634 4. Add 50 μL IH4-RBD reagent (2 $\mu\text{g}/\text{mL}$ in PBS = 100 ng/well) to Columns 1,3,5,7,9,11
635 5. Add 50 μL PBS to columns 2,4,6,8,10,12.
636 6. Inc 1 hr RT
637 7. Tilt for 30 seconds
638 8. Photograph: with mobile phone use the zoom function to obtain a complete field
639 9. Read as Positive = No teardrop, Negative <1:40 = partial teardrop, Neg = complete
640 teardrop.
641 10. Two readers should read the plates independently, and disagreements resolved by
642 taking the lesser reading.
643 11. For each batch of samples set up positive control wells containing 20-100 ng
644 monoclonal antibody CR3022 (as in Finger-Prick test below). This establishes that all
645 of the reagents are working.

646

647 **2. Titration of Stored Serum/Plasma Samples.**

- 648 1. Dilute samples to **1:20** in 50 μL PBS (2.5 μL to 47.5 μL) in V-bottomed plate in Rows A-
649 H, column 1.
- 650 2. Prepare doubling dilutions with PBS across the plate columns 1-11 (1:40 to 1:40,960),
651 PBS control in column 12. Eight samples can be titrated per 96-well plate.
- 652 3. Add 50 μL 1:40 O-ve red cells (1% v/v or 1:40 fresh EDTA O-ve blood sample) to all
653 wells
- 654 4. Add 50 μL IH4-RBD (2 $\mu\text{g}/\text{mL}$, = 100 ng/well). [Note: the red cells and IH4-RBD can be
655 pre-mixed and added together in either 50 μL or 100 μL volume, to save a step. This
656 variation in technique does not alter the measured titres.]
- 657 5. Allow red cells to settle for 1 hr
658 6. Tilt plate for at least 30 s and photograph. The titre is defined by the last well in which
659 the tear drop fails to form. Partial teardrop regarded as negative.

660

661 **3. Finger-prick test on capillary blood as a Point of Care Test**

- 662 1. Preparation: Clean Hands, warm digit. Prepare a plate (96-well V-bottomed) labelled
663 with Date and Time.
- 664 2. Prick skin on outer finger pulp with disposable, single use BD or another Lancet.
- 665 3. Wipe away first drop of blood with sterile towel/swab
- 666 4. Massage second drop
- 667 5. Take a minimum of 5 μL blood with 20 μL pipette, mix immediately into 20 μL K2EDTA
668 (3.6 mg/mL/PBS) in Eppendorf. If possible, take 20 μL of blood and mix into 80 μL
669 K2EDTA solution. Another approach is collection of blood drops into a BD Microtainer
670 K2E EDTA lavender vials that take 250-500 μL .
- 671 6. For 5 μL sample dilute to 200 μL with PBS (add 175 μL PBS), for 20 μL sample dilute to
672 800 μL (add 700 μL PBS). **Sample is now at 1:40, and the red cells are at the correct**
673 **density (~1% v/v assuming a haematocrit of 40%) to give a clear tear drop.**
- 674 7. Plate 50 μL x 3 in V bottomed microtitre wells labelled T (Test), + (PC, positive Control),
675 - (NC, negative control) – see figure 6.
- 676 8. Add 10 μL of control anti RBD Mab CR3022 (2 $\mu\text{g}/\text{mL}$ stock in PBS, 20 ng/well) to “+”
677 well
- 678 9. Add 50 μL IH4-RBD (2 $\mu\text{g}/\text{mL}$ in PBS) to “T” (Test) and “+ve” wells, 50 μL PBS to “-ve”
679 well.
- 680 10. Incubate 1 hour at RT for Red Cells to form a pellet in the “-ve” well
- 681 11. Tilt plate against a well-lit white background for ~30 seconds to allow Tear drop to
682 form in “-ve” well.
- 683 12. The presence of antibodies to RBD is shown by loss of Tear Drop formation in the “T”
684 and “+ve” wells. Occasionally a partial tear drop forms – these wells are counted as
685 Negative.
- 686 13. **Photograph the plate to record the results with the date and time.** Results can be
687 reviewed and tabulated later. Taking picture from a distance and using the zoom
688 function helps to take a clear picture of all wells in a 96-well plate.
- 689 14. The negative (PBS) control should be done on every sample for comparison. The
690 Positive control induced by CR3022 is used to check that all the reagents are working,
691 and that the glycoprotein epitope recognised by VHH(IH4) is present on the red cells.
692 Absence of the IH4 epitope should be *very rare* (Habib et al., 2013). For setting up

693 cohorts a positive control on every sample is therefore not necessary but should be
694 included in every *batch* of samples.

695 15. If a 20 μL sample of blood was taken from the finger prick there should be 650 μL of
696 the 1:40 diluted blood left. The red cells can be removed and a preparation of 1:40 O-
697 ve red cells used as above to titrate the sample. In principle the autologous red cells
698 could be washed repeatedly, resuspended in the same volume of PBS, and used as
699 indicators for the titration, however we have not attempted to do this. The s/n is 1:40
700 plasma that can be used in confirmatory ELISA or other tests.

701

702 **Author Contributions**

703 **Conceived, initiated and followed the project, documented portability and robustness of**
704 **HAT method in a separate laboratory, recruited collaborators:** Etienne Joly.

705 **Designed and produced the IH4-RBD reagent, established conditions for lyophilisation,**
706 **isolated and expanded human monoclonal antibodies to the RBD and ACE2-Fc, performed**
707 **the standard HAT assays, wrote the paper:** Alain Townsend, Pramila Rijal, Julie Xiao, Tiong
708 Kit Tan, Lisa Schimanski, Jiangdong Huo, Rolle Rahikainen, Kuan-Ying A Huang.

709 **Contributed examples of HAT as a Point of Care Test:** Nimesh Gupta.

710 **Provision of Serum/Plasma Sample Sets for Figure 4: Project management for Oxford**
711 **serology work for sensitivity and specificity measurement, assessment of preliminary data:**
712 Philippa Matthews, Derrick Crook, Sarah Hoosdally, Nicole Stoesser; **collection and**
713 **processing of samples, coordination of sample banks and running Siemens assay, ethics,**
714 **storage of pre-pandemic samples, coordination of provision of pre-pandemic samples from**
715 **Oxford BioBank, and sero-positive donors through NHSBT :** Teresa Street, Justine Rudkin,
716 Fredrik Karpe, Matthew Neville, Rutger Ploeg, David J Roberts, Abbie Bown, Richard Vipond,
717 Marta Oliveira, Abigail A Lamikanra, Hoi Pat Tsang.

718 **Provision of Serum Sample Sets for Figure 5 and Table 1 (COMBAT samples):** Alexander J
719 Mentzer, Julian C Knight, Andrew Kwok, Paul Klenerman, Christina Dold; **ISARIC4C**
720 **Investigators:** J. Kenneth Baillie, Shona C Moore, Peter JM Openshaw, Malcolm G Semple,
721 Lance CW Turtle; **Oxford Immunology Network Covid-19 Response Clinical Sample**
722 **Collection Consortium:** Mark Ainsworth, Alice Allcock, Sally Beer, Sagida Bibi, Elizabeth
723 Clutterbuck, Alexis Espinosa, Maria Mendoza, Dominique Georgiou, Teresa Lockett, Jose

724 Martinez, Elena Perez, Veronica Sanchez, Giuseppe Scozzafava, Alberto Sobrinodiaz, Hannah
725 Thraves.

726

727 **ACKNOWLEDGEMENT AND FUNDING**

728 A.T. is funded by the Medical Research Council (MR/P021336/1), Townsend-Jeantet
729 Charitable Trust (charity number 1011770) and the Chinese Academy of Medical Sciences
730 (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant no. 2018-I2M-2-002). N.G.
731 is funded by the Science Engineering Research Board, Department of Science and Technology,
732 India. P.C.M. is funded by the Wellcome Trust (grant ref 110110Z/15/Z). D.R. is supported by
733 NIHR Oxford Biomedical Research Centre. National Institute for Health Research Biomedical
734 Research Centre Funding Scheme (to G.R.S.), the Chinese Academy of Medical Sciences
735 (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant number: 2018-I2M-2-
736 002). G.R.S. is supported as a Wellcome Trust Senior Investigator (grant 095541/A/11/Z).

737

738 The Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus 2
739 Wuhan-Hu-1 (Figure 6), Recombinant from HEK293 Cells, NR-52306 was produced under
740 HHSN272201400008C and obtained through BEI Resources, NIAID, NIH.

741

742 We thank the healthy volunteers who kindly donated their O-ve red cells for titration of
743 samples.

744

745 **DECLARATION**

746 Competing Interests none.

747 The views expressed are those of the author(s) and not necessarily those of the NHS, the
748 NIHR, the Department of Health or Public Health England'.

749

750 **REFERENCES**

751

752 Adams, Emily R., Ainsworth, Mark, Anand, Rekha, Andersson, Monique I., Auckland, Kathryn, Baillie,
753 J. Kenneth, . . . Whitehouse, James. (2020). Antibody testing for COVID-19: A report from
754 the National COVID Scientific Advisory Panel. *Wellcome Open Research*, 5.
755 doi:10.12688/wellcomeopenres.15927.1

756 Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., . . .
757 Krammer, F. (2020). A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat*
758 *Med*, 26(7), 1033-1036. doi:10.1038/s41591-020-0913-5

759 Barnes, C. O., West, A. P., Jr., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., .
760 . . Bjorkman, P. J. (2020). Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal
761 Common Epitopes and Recurrent Features of Antibodies. *Cell*, 182(4), 828-842 e816.
762 doi:10.1016/j.cell.2020.06.025

763 Coombs, R. R., Mourant, A. E., & Race, R. R. (1945). A new test for the detection of weak and
764 incomplete Rh agglutinins. *Br J Exp Pathol*, 26, 255-266.

765 Dai, L., Zheng, T., Xu, K., Han, Y., Xu, L., Huang, E., . . . Gao, G. F. (2020). A Universal Design of
766 Betacoronavirus Vaccines against COVID-19, MERS, and SARS. *Cell*, 182(3), 722-733 e711.
767 doi:10.1016/j.cell.2020.06.035

768 Habib, I., Smolarek, D., Hattab, C., Grodecka, M., Hassanzadeh-Ghassabeh, G., Muyltermans, S., . . .
769 Bertrand, O. (2013). V(H)H (nanobody) directed against human glycoporphin A: a tool for
770 autologous red cell agglutination assays. *Anal Biochem*, 438(1), 82-89.
771 doi:10.1016/j.ab.2013.03.020

772 Hanson, K. E., Caliendo, A. M., Arias, C. A., Englund, J. A., Hayden, M. K., Lee, M. J., . . . Mustafa, R. A.
773 (2020). Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-
774 19:Serologic Testing. *Clin Infect Dis*. doi:10.1093/cid/ciaa1343

775 Hirst, G. K. (1941). The Agglutination of Red Cells by Allantoic Fluid of Chick Embryos Infected with
776 Influenza Virus. *Science*, 94(2427), 22-23. doi:10.1126/science.94.2427.22

777 Huang, Kuan-Ying A., Tan, Tiong Kit, Chen, Ting-Hua, Huang, Chung-Guei, Harvey, Ruth, Hussain, Saira,
778 . . . Townsend, Alain R. (2020). Plasmablast-derived antibody response to acute SARS-CoV-2
779 infection in humans. *bioRxiv*. doi:10.1101/2020.08.28.267526

780 Huo, J., Le Bas, A., Ruza, R. R., Duyvesteyn, H. M. E., Mikolajek, H., Malinauskas, T., . . . Naismith, J. H.
781 (2020). Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
782 *Nat Struct Mol Biol*, 27(9), 846-854. doi:10.1038/s41594-020-0469-6

783 Huo, J., Zhao, Y., Ren, J., Zhou, D., Duyvesteyn, H. M. E., Ginn, H. M., . . . Stuart, D. I. (2020).
784 Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. *Cell Host Microbe*, 28(3),
785 497. doi:10.1016/j.chom.2020.07.002

786 Kruse, Robert L., Huang, Yuting, Smetana, Heather, Gehrie, Eric A., Amukele, Tim K., Tobian, Aaron A.
787 R., . . . Wang, Zack Z. (2020). A rapid, point of care red blood cell agglutination assay for
788 detecting antibodies against SARS-CoV-2. *bioRxiv*. doi:10.1101/2020.05.13.094490

789 Lan, Jun, Ge, Jiwan, Yu, Jinfang, Shan, Sisi, Zhou, Huan, Fan, Shilong, . . . Wang, Xinquan. (2020). Crystal
790 structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor.
791 *bioRxiv*. doi:10.1101/2020.02.19.956235

792 Landsteiner, K. (1961). On agglutination of normal human blood. *Transfusion*, 1, 5-8.
793 doi:10.1111/j.1537-2995.1961.tb00005.x

794 Li, F., Li, W., Farzan, M., & Harrison, S. C. (2005). Structure of SARS coronavirus spike receptor-binding
795 domain complexed with receptor. *Science*, 309(5742), 1864-1868.
796 doi:10.1126/science.1116480

797 Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., . . . Jansen, K. U. (2020).
798 Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature*. doi:10.1038/s41586-
799 020-2639-4

800 Pamphilon, D. H., & Scott, M. L. (2007). Robin Coombs: his life and contribution to haematology and
801 transfusion medicine. *Br J Haematol*, 137(5), 401-408. doi:10.1111/j.1365-2141.2007.06531.x

802 Peng, Y., Mentzer, A. J., Liu, G., Yao, X., Yin, Z., Dong, D., . . . Dong, T. (2020). Broad and strong memory
803 CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following
804 COVID-19. *Nat Immunol*. doi:10.1038/s41590-020-0782-6

805 Piccoli, Luca, Park, Young-Jun, Tortorici, M. Alejandra, Czudnochowski, Nadine, Walls, Alexandra C.,
806 Beltramello, Martina, . . . Veesler, David. (2020). Mapping neutralizing and immunodominant
807 sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution
808 serology. *Cell*. doi:10.1016/j.cell.2020.09.037

809 Pinto, D., Park, Y. J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., . . . Corti, D. (2020). Cross-
810 neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature*, 583(7815),
811 290-295. doi:10.1038/s41586-020-2349-y

812 Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., . . . Nussenzweig, M. C.
813 (2020). Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature*,
814 584(7821), 437-442. doi:10.1038/s41586-020-2456-9

815 Schwarz, H. P., & Dorner, F. (2003). Karl Landsteiner and his major contributions to haematology. *Br J*
816 *Haematol*, 121(4), 556-565. doi:10.1046/j.1365-2141.2003.04295.x

817 Tan, Tiong Kit, Rijal, Pramila, Rahikainen, Rolle, Keeble, Anthony H., Schimanski, Lisa, Hussain, Saira, .
818 . . Townsend, Alain R. (2020). COVID-19 vaccine candidate using SpyCatcher multimerization
819 of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising
820 antibody responses. *bioRxiv*. doi:10.1101/2020.08.31.275701

821 ter Meulen, J., van den Brink, E. N., Poon, L. L., Marissen, W. E., Leung, C. S., Cox, F., . . . Goudsmit, J.
822 (2006). Human monoclonal antibody combination against SARS coronavirus: synergy and
823 coverage of escape mutants. *PLoS Med*, 3(7), e237. doi:10.1371/journal.pmed.0030237

824 The National SARS-CoV-2 Serology Assay Evaluation Group, The National SARS-CoV-2 Serology Assay
825 Evaluation Group. (2020). *Manuscript preprint: Head-to-head benchmark evaluation of the*
826 *sensitivity and specificity of five immunoassays for SARS-CoV-2 serology on >1500 samples.*

827 Walls, A. C., Fiala, B., Schafer, A., Wrenn, S., Pham, M. N., Murphy, M., . . . King, N. P. (2020). Elicitation
828 of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-
829 CoV-2. *bioRxiv*. doi:10.1101/2020.08.11.247395

830 Wang, Q., Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., . . . Qi, J. (2020). Structural and Functional Basis
831 of SARS-CoV-2 Entry by Using Human ACE2. *Cell*, 181(4), 894-904 e899.
832 doi:10.1016/j.cell.2020.03.045

833 Wegmann, T. G., & Smithies, O. (1966). A Simple Hemagglutination System Requiring Small Amounts
834 of Red Cells and Antibodies. *Transfusion*.

835 Wrapp, D., De Vlieger, D., Corbett, K. S., Torres, G. M., Wang, N., Van Breedam, W., . . . McLellan, J. S.
836 (2020). Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain
837 Camelid Antibodies. *Cell*, 181(6), 1436-1441. doi:10.1016/j.cell.2020.05.047

838 Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020). Structural basis for the recognition of SARS-
839 CoV-2 by full-length human ACE2. *Science*, 367(6485), 1444-1448.
840 doi:10.1126/science.abb2762

841 Yang, J., Wang, W., Chen, Z., Lu, S., Yang, F., Bi, Z., . . . Wei, X. (2020). A vaccine targeting the RBD of
842 the S protein of SARS-CoV-2 induces protective immunity. *Nature*. doi:10.1038/s41586-020-
843 2599-8

844 Zha, Lisha, Zhao, Hongxin, Mohsen, Mona O., Hong, Liang, Zhou, Yuhang, Li, Zehua, . . . Wang, Junfeng.
845 (2020). Development of a COVID-19 vaccine based on the receptor binding domain displayed
846 on virus-like particles. *bioRxiv*. doi:10.1101/2020.05.06.079830

847 Zhou, D., Duyvesteyn, H. M. E., Chen, C. P., Huang, C. G., Chen, T. H., Shih, S. R., . . . Huang, K. A. (2020).
848 Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent
849 patient. *Nat Struct Mol Biol*. doi:10.1038/s41594-020-0480-y

850


851 **SUPPLEMENTARY DATA**

852

853 Supplementary Table 1. Fifteen human monoclonal antibodies or nanobodies with endpoint
 854 titres for detection in the HA Test. One divalent nanobody VHH72-Fc and two monoclonal
 855 antibodies FD-5D and EZ-7A specific for the RBD failed to agglutinate red cells with the IH4-
 856 RBD reagent. Three monoclonal antibodies to other regions of the spike protein EW-8B, EW-
 857 9C and FJ-1C acted as negative controls.

858

| Mab or divalent Nanobody | HAT endpoint titre (ng/well) | Reference |
|--------------------------|------------------------------|--|
| CR3022 | 2 | (Huo, Zhao, et al., 2020; ter Meulen et al., 2006) |
| EY-6A | 16 | (Zhou et al., 2020) |
| VHH-72-Fc | Negative | (Wrapp et al., 2020) |
| FI-4A | 16 | (Huang et al., 2020) |
| ACE2-Fc | 4 | (Huo, Le Bas, et al., 2020) |
| FI-3A | 8 | (Huang et al., 2020) |
| FI-1C | 4 | (Huang et al., 2020) |
| H11-H4-Fc | 16 | (Huo, Le Bas, et al., 2020) |
| FD-5D | Negative | (Huang et al., 2020) |
| FD-11A | 31 | (Huang et al., 2020) |
| FN-12A | 31 | (Huang et al., 2020) |
| FJ-10B | 62 | (Huang et al., 2020) |
| FM-7B | 62 | (Huang et al., 2020) |
| EZ-7A | Negative | (Huang et al., 2020) |
| S309 | 125 | (Pinto et al., 2020) |
| EW-8B non-RBD anti Spike | Neg Control | (Huang et al., 2020) |
| EW-9C non-RBD anti Spike | Neg Control | (Huang et al., 2020) |
| FJ-1C anti NTD | Neg Control | (Huang et al., 2020) |




860

861 Supplementary Figure 1 A, B) Three MAbs or Nanobody-Fc reagents of 15 tested specific for
 862 RBD failed to cross-link red cells but could be developed with an anti IgG reagent. Antibodies
 863 were titrated from 500 ng/well to 1 ng/well in 50 μ L, 1:40 red cells were added in 50 μ L,
 864 followed by 100 ng/well IH4-RBD in 50 μ L, and incubated for 1 hour. The labelled red cells
 865 were then resuspended, and either 50 μ L PBS (L hand plates), or Sigma Clone GG5 anti human
 866 IgG 1:100 in 50 μ L (R hand plates). Red cells were allowed to settle for one hour, the plate
 867 tilted for 30s and photographed.

868

869




Slope = 0.94 (95% CI 0.92 - 0.96)


Suggests second set has tendency to detect ~1 doubling dilution (DD) lower titres

230/232 (99%) were within 1 DD

B Titration in HAT by doubling dilution (Repeat)



Donors were grouped according to clinical criteria; HCW = Front Line Health Care Workers; Sepsis = Samples with patients with Sepsis prior to Covid-19 pandemic; Healthy = Healthy volunteers prior to Covid-19; DD 1 = 1:40. Actual Titre = 20×2^{DD} .



| | HAT +ve | HAT -ve | Total | Fraction |
|-------------|---------|---------|-------|----------|
| Siemens +ve | 108 | 5 | 113 | 0.96 |
| Siemens -ve | 16 | 24 | 40 | 0.40 |
| Total | 124 | 29 | 153 | 0.81 |
| Fraction | 0.87 | 0.83 | 0.74 | |

| P value and statistical significance | |
|--------------------------------------|---------------------|
| Test | Fisher's exact test |
| P value | <0.0001 |
| P value summary | **** |
| One- or two-sided | Two-sided |

Sensitivity (Sn) HAT 81%, Sn Siemens 74%
 HAT still more sensitive than Siemens

Specificity 100% for HAT in these samples

870

871 Supplementary Figure 2

872 A) The 232 samples from figure 5 in the main paper were titrated a second time 34 days after
 873 the first measurement, as described for figure 4 (Methods). The values for the end point
 874 doubling dilution were compared and a correlation coefficient, and slope calculated (Prism
 875 v8).

876 B) The collection included 32 samples from 24 Critical patients, 62 samples from 48 Severe,
877 39 samples from 32 Mild, 20 single samples from health care workers (HCW), 54 samples from
878 43 patients with unrelated sepsis in the pre-Covid-19 era, 25 samples from healthy unexposed
879 controls. Median is shown.

880 C) Comparison to Siemens Result (anti RBD) with HAT Titre by Doubling Dilution for 153
881 samples from Critical, Severe, Mild and HCW PCR+ve donors. The sensitivity of the HAT in this
882 repeat was 81%, v 86% in the first test.

883

884 **DNA sequence of codon optimised cDNA encoding IH4-RBD**

885 ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTTTCATAGCCAGGTC
886 CAGCTGCAAGAGTCTGGCGGAGGATCTGTTCAGGCTGGCGGAAGCCTGAGACTGAGCTGTGT
887 GGCCAGCGGCTACACCGATAGCACATACTGCGTCGGCTGGTTCAGACAGGCCCTGGCAAAG
888 AGAGAGAGGGCGTCGCCAGAATCAACACCATCAGCGGCAGACCTTGGTACGCCGACTCTGTG
889 AAGGGCAGATTCACAATCAGCCAGGACAACAGCAAGAACACCGTGTTTCTGCAGATGAACA
890 GCCTGAAGCCAGAGGACACCGCCATCTACTACTGCACCCTGACCACCGCCAACAGCAGAGGC
891 TTTTGTTCGGCGGCTACAACATAAAGGCCAGGGCACCCAAGTGACCGTGTCTAGCGCGTC
GACCGGCTCTGGCGGCAGCGGCAACATCACCAATCTGTGCCCTTTCGGCGAGGTGTTCAACG
CCACCAGATTTGCCAGCGTGTACGCCTGGAACCGGAAGAGAATCAGCAACTGCGTGGCCGAC
TACAGCGTGCTGTACAATAGCGCCAGCTTCAGCACCTTCAAGTGCTACGGCGTGTCCCCTACC
AAGCTGAACGACCTGTGCTTCACCAATGTGTACGCCGACAGCTTCGTGATCAGAGGCGACGA
AGTTCCGGCAGATCGCTCCTGGACAGACAGGCAAGATCGCCGATTACAACATAAAGCTGCCCG
ACGACTTACACCGGCTGCGTGATCGCCTGGAATAGCAACAACCTGGACAGCAAAGTCGGCGGC
AACTACAACCTGTACCGGCTGTTCCGGAAGTCCAACCTGAAGCCTTTCGAGCGGGACAT
CAGCACCGAGATCTATCAGGCCGGCAGCACCCCTTGTAATGGCGTGGAAGGCTTCAACTGCT
ACTTCCCCTGCAGTCTACGGCTTTCAGCCTACAACGGCGTGGGCTACCAGCCTTATAGAG
TGGTGGTGCTGAGCTTCGAACTGCTGCATGCCCTGCTACCGTGTGCGGCCCTAAAAACACC
ATCACCACCACCATTGA